Association Between Trimethylamine-N-oxide & Gestational Diabetes Mellitus

Status Completed

Clinical Trial Summary

Background: The microbiota-dependent metabolite trimethylamine-N-oxide (TMAO) has been reported as a novel and independent risk factor for the development of cardiovascular and metabolic diseases, but the association with gestational diabetes mellitus (GDM) remains unclear.

Objective: To investigate the association between plasma TMAO concentration and GDM in a two-phase study.

Design: The initial discovery phase included 866 pregnant women (433 GDM cases and 433 matched controls) in Wuhan China. Study participants were recruited from pregnant women who attended the outpatient clinics of the Department of Endocrinology, Tongji Hospital, to screen for GDM between August 2012 and April 2015, or pregnant women who visited the Hubei Maternal and Child Health Hospital or the Central Hospital of Wuhan for a routine antenatal checkup from May 2014 to November 2016. The inclusion criteria of participants were: age ≥ 20 years, gestational age between 24 and 32 weeks, no history of a diagnosis of diabetes or gestational diabetes, and no history of receiving pharmacological treatment known to affect glucose metabolism. An independent replication phase study was nested within an ongoing prospective cohort study, namely the Tongji Maternal and Child Health Cohort (TMCHC). Beginning in January 2013, women receiving prenatal care prior to 16 weeks of gestation were invited to join the TMCHC. Exclusion criteria included pre-pregnancy diabetes, clinically significant neurological, endocrinological or other systemic diseases and multiple pregnancies. All enrolled pregnant women received a regular prenatal checkup in hospital and underwent an oral glucose tolerance test (OGTT) during 24-32 weeks of gestation to screen for GDM. 276 members who developed GDM before May 2016 and had fasting blood collected before 20 weeks'gestation were included as cases in this analysis. Two controls were individually matched to each case from among women without GDM. These two studies were approved by the ethics committee of Tongji Medical College. All the participants gave informed written consent before they were included in the study. Plasma TMAO concentrations were determined by stable isotope dilution liquid chromatography with online electrospray ionization tandem mass spectrometry.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03415295
Study type	Observational
Source	Huazhong University of Science and Technology
Contact
Status	Completed
Phase	N/A
Start date	August 1, 2012
Completion date	June 30, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05081037` - Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)	N/A
Active, not recruiting	`NCT03249896` - Web/Smartphone-based Lifestyle Coaching Program in Pregnant Women With Gestational Diabetes	N/A
Terminated	`NCT03749889` - Low Carb vs Normal Carb in Pregnancy	N/A
Completed	`NCT03859193` - Education Nutritional Video for Gestational Diabetics	N/A
Recruiting	`NCT05037526` - Utility of Real Time Continuous Glucose Monitoring in the Care of Gestational Diabetes Versus Standard Care in Pregnancy Outcomes	N/A
Completed	`NCT06178250` - Placenta, Fetal Liver, Sectional Ductus Venosus Volumes Examined by Three-dimensional Ultrasound in the Second Trimester	N/A
Not yet recruiting	`NCT06445530` - Nutrition Optimization and Community Upliftment for Postpartum Recovery	N/A
Not yet recruiting	`NCT06310356` - Continuous Glucose Monitoring for Women With Gestational Diabetes	N/A
Recruiting	`NCT02590016` - Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial	Phase 4
Not yet recruiting	`NCT00883259` - Metformin and Gestational Diabetes in High-risk Patients: a RCTs	Phase 4
Withdrawn	`NCT01947699` - Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide	Phase 4
Recruiting	`NCT03008824` - Micronutrients in Pregnancy as a Risk Factor for Diabetes and Effects on Mother and Baby	N/A
Active, not recruiting	`NCT01340924` - Relationship Between Gestational Diabetes and Type 2 Diabetes
Completed	`NCT00534105` - Lipid Metabolism in Gestational Diabetes	N/A
Recruiting	`NCT00371306` - Comparison of Glucovance to Insulin for Diabetes During Pregnancy	N/A
Completed	`NCT03388723` - Intergenerational Programming of Diabesity in Offspring of Women With Gestational Diabetes Mellitus
Recruiting	`NCT04521712` - Postpartum Glycemia in Women at Risk For Persistent Hyperglycemia	N/A
Enrolling by invitation	`NCT03307486` - Gestational Diabetes: a Cohort Study	N/A
Active, not recruiting	`NCT03301792` - Group Versus Traditional Prenatal Care for Diabetes	N/A
Enrolling by invitation	`NCT05603793` - YoUng Adolescents' behaViour, musculoskeletAl heAlth, Growth & Nutrition

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Association Between Trimethylamine-N-oxide and Gestational Diabetes Mellitus

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms